NCT05505253View on ClinicalTrials.gov

Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 1, 2020

Primary Completion Date

October 31, 2021

Study Completion Date

December 31, 2021

Conditions
Pelvic Organ Prolapse
Interventions
DRUG

Alfacalcidol 0.0005 MG

Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured

DRUG

Placebo

Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured

Trial Locations (1)

40161

Universitas Padjadjaran, Bandung

All Listed Sponsors
lead

Universitas Padjadjaran

OTHER

NCT05505253 - Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients | Biotech Hunter | Biotech Hunter